Journal of Surgery and Surgical Research Citation: Mrabent MN, Harir N, Sellam F, Zeggai S, Tou A, et al. (2015) HER2 Status in Male Breast Carcinoma: a Single North African Institution Experience of 10 Cases and Review of the Literature. J Surg Surgical Res 1(3): 049-050. 049 Abstract Background: To investigate clinic-pathological characteristics, hormonal receptors and HER2 receptor of male breast cancer. Materials and methods: Retrospective study of 10 cases between 2010 and 2013. The studied parameters were: tumor size, histological type, histological grade, lymph node status, hormonal status and overexpression of HER2. Results: The average age of our patients was 60.2 years, in 70% of cases; the histological size that was found was T4; and iniltrating ductal carcinoma was diagnosed in all cases. The grades classiication was as follow: grade 2 (30%) and grade 3 (70%). 70% of cases had lymph node metastasis. Estrogen and progesterone receptors (ER,PR) were positive in 60% of tumors. Overexpression of HER2 was positive (Score3) in one case. Luminal B was the most common subtype in our study. Conclusion: Male breast cancer is a rare disease with a poor prognosis despite the recent increase in incidence in recent years. The diagnosis is often delayed and injuries are treated in advanced stages. Material and Method his cross sectional study was done at the department of pathology at Sidi Bel Abbes University Hospital in Western Algeria from 2010 to 2013. he Male patients with breast cancer were selected for the study. he cases were stained with hematoxyline and eosin (H&E) for routine histological examination. An absolute conidentiality of the patients’ vital information was maintained for ethical purposes and an ethical approval was obtained from institutions in which the study was carried out. We used immunohistochemistry to evaluate the expression of HER2, ER, and PR receptor. Immunohistochemical expression of HER2 was evaluated according to the published scoring guidelines of the ‘HercepTest’ (Dako, Carpinteria, CA). Herceptest of score 3+ was considered as positive. Four subtypes were deined: 1) Luminal A; oestrogen receptor (ER) + and/or progesterone receptor (PR) +, HER2 -, grade 1 or grade 2 tumours, 2) Luminal B; ER + and/or PR + and HER2 + tumours or ER+ and /or PR+ and HER2- grade 3 tumours, 3) HER2+; ER -, PR- and HER2 + tumours, 4) Triple negative; ER-, PR-,HER2- tumours. Graph and circles were done using the SPSS Inc. sotware (Version20). Results 10 patients with breast cancer were included; and all of them were men. Median age was about 60.2 years (range, 42-80); he most Introduction Breast cancer in men is a rare disease and makes up approximately 1% of all cases of breast cancer [1,2]. he rarity of this entity precludes prospective randomized trials. During 2014 in the USA, about 2,360 new cases of invasive breast cancer were diagnosed in men and about 430 men died from the disease [3]. he etiology of male breast cancer is unclear, but hormone levels and testicular abnormalities play a role in the development of this disease [4,5]. Other recognized risk factors include radiation exposure, family history of breast cancer, Klinefelter syndrome, and diferent benign breast conditions [4,5]. Previous reports have suggested that cancers of the male breast are more likely than female breast cancers to have a ductal histology and are signiicantly more likely to express hormone receptors [6,7]. Early reports suggested equivalent or even higher rates of human epidermal growth factor receptor 2 (HER2) overexpression in male breast cancer versus female breast cancer [8,9]. Overexpression of the oncoprotein HER2 observed in 10-15% of patients could justify prescribing trastuzumab. In the context of the considerable progress achieved in the recent years concerning female’s breast cancer management, it seems important to review the acquired data and to exploit these advances in order to improve male breast cancer care [10]. In this study we will explore the following pathological parameters: histological type, tumor size, histological grade, lymph node status, hormonal and HER2 status of male breast cancer from western Algeria and compared them with diferent literatures data. Research Article HER2 Status in Male Breast Carcinoma: a Single North African Institution Experience of 10 Cases and Review of the Literature Meriem N Mrabent 1 , Noria Harir 1 , Feriel Sellam 1 *, Soumia Zeggai 1 , Abdenacer Tou 2 , Mustapha Diaf 1 , Rachida Salah1 and Soraya Moulesshoul 1 1 Laboratory of Molecular Microbiology, Proteomics and Health, Departement of Biology, Djillali Liabes University of Sidi bel Abbes, Algeria 2 Department of Pathology; Hospital of Sidi bel Abbes, Algeria Dates: Received: 12 September, 2015; Accepted: 26 October, 2015; Published: 28 October, 2015 *Corresponding author: Feriel Sellam, PhD., Department of Biology, Djillali Liabes University of Sidi bel Abbes, (Ex ITMA), Algeria candidate in Cellular Biology and Pathology, E-mail: www.peertechz.com Keywords: Breast cancer; Man; Overexpression; ER; PR; HER2